Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Business & Finance
Lymphoseek maker reports annual revenue increase of 32%
April 6th, 2004
Neoprobe Corp. (NEOP) announced financial results for the fourth quarter of 2003 and for the full year that ended December 31, 2003. Results for the fourth quarter and for the full year of 2003 include the consolidated operations of Neoprobe Corp. and its wholly owned subsidiary, Cardiosonix, Ltd. For the fourth quarter of 2003, Neoprobe had a net loss of $582,000 or $0.01 per share. For fiscal year 2003, Neoprobe incurred a loss of $1.8 million or $0.04 per share. The net loss decreased by 39% compared to the prior year. For the year 2003, Neoprobe reported revenues of $6.5 million compared to $4.9 million in the prior year....
Source: Cancer Weekly (2004-04-06)
|
